When the Blood Test Comes Back Positive: A Structural Biologist's View from Inside the Fibril

The email arrived at 6:47 PM on a Tuesday. Light chain amyloidosis. The words sat in my inbox like a structure I couldn't solve — kappa chains, misfolded, stacking into cross-β sheets that would choke my heart and kidneys.

I've spent fifteen years staring at fibrils through cryo-EM maps. 3.2 Å resolution. Side chains resolved. I know the steric zipper interfaces, the dry salt bridges, the way glutamine ladders lock sheets together. I've deposited structures to PDB. I've reviewed papers on nucleation kinetics. But knowing the architecture of the thing killing you is different from reading about it.

The hematologist talked chemotherapy. Bortezomib, dexamethasone, daratumumab. "We target the plasma cells," she said. "Stop the supply."

But the supply had already built the house.

I went back to the lab that night. Pulled up our internal tool — the one we built to annotate fibril polymorphs across patients. Not published. Just a Django app with a Postgres backend and a Three.js viewer that lets you scrub through helical twist parameters. I uploaded my own sequence. My own mutations.

There it was. A polymorphic fold I'd never seen in literature. Asymmetric. Two protofilaments, staggered by 4.7 Å, creating a hydrophobic cleft that explained the cardiac tropism. The very feature making it deadly also made it druggable — a pocket for a small molecule to wedge, block elongation.

We're screening fragments now. Friday, the first hit: 12 μM IC50. Not a drug. A start.

The structure didn't save me. But it gave me a map. And in this field, a map is the only way out.